CoChat

Clomiphene citrate for men with hypogonadism: a systematic review and meta‐analysis

Open access

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.

Abstract

Background: Male hypogonadism is a clinical and biochemical androgen insufficiency syndrome, becoming more prevalent with age. Exogenous testosterone is first‐choice therapy, with several side effects, including negative feedback of the hypothalamic–pituitary–gonadal axis, resulting in suppression of intratesticular testosterone production and spermatogenesis. To preserve these testicular functions while treating male hypogonadism, clomiphene citrate is used as off‐label therapy. This systematic review and meta‐analysis aimed to evaluate the effectiveness and safety of clomiphene citrate therapy for men with hypogonadism. Methods: The EMBASE, PubMed, Cochrane databases were searched in May 2021, for effectiveness studies of men with hypogonadism treated with clomiphene citrate. Both intervention and observational studies were included. The Effective Public Health Practice Project Quality Assessment Tool, a validated instrument, was used to assess methodological study quality. The primary outcome measure was the evaluation of serum hormone concentration. Secondary outcomes were symptoms of hypogonadism, metabolic and lipid profile, side effects, safety aspects. Results: We included 19 studies, comprising four randomized controlled trials and 15 observational studies, resulting in 1642 patients. Seventeen studies were included in the meta‐analysis, with a total of 1279 patients. Therapy and follow‐up duration varied between one and a half and 52 months. Total testosterone increased with 2.60 (95% CI 1.82–3.38) during clomiphene citrate treatment. An increase was also seen in free testosterone, luteinizing hormone, follicle stimulating hormone, sex hormone‐binding globulin and estradiol. Different symptom scoring methods were used in the included studies. The most frequently used instrument was the Androgen Deficiency in Aging Males questionnaire, whose improved during treatment. Reported side effects were only prevalent in less than 10% of the study populations and no serious adverse events were reported. Conclusion: Clomiphene citrate is an effective therapy for improving both biochemical as well as clinical symptoms of males suffering from hypogonadism. Clomiphene citrate has few reported side effects and good safety aspects.

Overview

Integrity signals

Registry

Crossref · 10.1111/andr.13146

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 68 references

Research works printed but not linked: 4

  1. Dohle G, 2015, Guidelines on male hypogonadism, Eur Assoc Urol
  2. Review Manager (RevMan). Version 5.4. The Cochrane Collaboration;2020.
  3. Guay A, 1995, Effect of raising endogenous testosterone impotent, J Clin Endocrinol Metab, 80, 3546
  4. Dohle GR, 2018, European Association of Urology (EAU) guidelines on male hypogonadism, Journal of Reproductive Medicine and Endocrinology

Cited by

Metadata

Authors
Huijben, M., Lock, M. T. W. T., de Kemp, V. F., de Kort, L. M. O., & van Breda, H. M. K.
Affiliations
  • University Medical Center Utrecht (NL)
  • Department of Urology University Medical Centre Utrecht Utrecht The Netherlands
Corresponding author
Huijben, Manou
Venue
Andrology
Publisher
Wiley
Published
2022-01-08
Volume
10
Issue
3
Pages
451-469
ISSN
  • 2047-2919 (ISSN-L)
  • 2047-2927
OpenAlex
W4200411621
Cited by
65
References
68
Citations by year
2026: 15 · 2025: 9 · 2024: 15 · 2023: 15 · 2022: 11
FWCI
1.38
Type
journal article
Language
en
Open access
Locations
  • Andrology (publishedVersion)
  • PubMed (publishedVersion)
  • Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
Keywords
clomiphene citrate, male hypogonadism, androgen deficiency, testosterone, free testosterone, luteinizing hormone, follicle-stimulating hormone, sex hormone-binding globulin, estradiol, off-label therapy, adverse effects, lipid profile
MeSH terms
Clomiphene, Follicle Stimulating Hormone, Humans, Hypogonadism, Luteinizing Hormone, Male, Testosterone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.